CareLit · DOI-Nachweis · Geburtshilfe und Frauenheilkunde
AGO-Cervix-1 study: A prospective, randomized phase III study to compare the effects of Paclitaxel and Topotecan to those of Cisplatin and Topotecan for treatment of patients with recurrent or persistent cervical cancer
DOI 10.1055/s-2008-1079196
Bibliografische Angaben
Nachweis in CareLit
Autor:innenF Thiel, DT Rein, IB Runnebaum, KU Petry, PA Fasching, MW Beckmann
ZeitschriftGeburtshilfe und Frauenheilkunde
Ausgabe05/2008
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
In patients with recurrent, persistent, or metastasized cervical cancer for which a curative treatment by operation and/or radiation therapy is not possible chemotherapy is an option. But up to 75% of all these patients are assumed to have already been treated with cisplatin in conjunction with radiation therapy. It seems questionable to continue to treat the patients with cisplatin. The studies GOG 169 and 179 demo…
Zitieren
Zitierempfehlung
F Thiel, DT Rein, IB Runnebaum, KU Petry, PA Fasching, MW Beckmann (2008) AGO-Cervix-1 study: A prospective, randomized phase III study to compare the effects of Paclitaxel and Topotecan to those of Cisplatin and Topotecan for treatment of patients with recurrent or persistent cervical cancer. Geburtshilfe und Frauenheilkunde (05). https://doi.org/10.1055/s-2008-1079196
Mit CareLit weiterarbeiten